Shanghai Green Valley Pharmaceuticals (Green Valley) announced today that China's National Medical Products Administration ( ANPM ) has approved oligo manato (GV-971) as a new drug for treatment of "Alzheimer's disease (AD) from benign to moderate and to improve cognitive function".

Shanghai Green Valley Pharmaceuticals (Green Valley) today announced that China's National Medical Products Administration (NMPA) has approved Oligomannate (GV-971) as new drug for the treatment of "mild to moderate Alzheimer's disease (AD) and improving cognitive function."

An expert panel reviews the causes of Alzheimer disease, as well as strategies used to detect mild cases and cognitive impairment.

At the American Academy of Neurology Annual Meeting held in Philadelphia, Pennsylvania, Jeffrey L. Cummings, MD, ScD, the director emeritus of the Cleveland Clinic Lou Ruvo Center for Brain Health and vice chair of the department of brain health at the University of Nevada Las Vegas, spoke with NeurologyLive in an interview to discuss therapies currently being investigated for the treatment of Alzheimer disease.

The Cleveland Clinic’s fourth annual Alzheimer disease (AD) drug development pipeline presents a new round of clinical trials to give clinicians a comprehensive look at current research in the US. The investigators, led by Jeffrey Cummings, MD, ScD, director emeritus of Cleveland Clinic Lou Ruvo Center for Brain Health, identified all pharmacologic Alzheimer trials currently in development from Clinicaltrials.gov. They found 132 agents currently in 156 clinical trials— 28 of which are in 42 phase 3 trials; 74 in 83 phase 2 trials; and 30 in 31 phase 1 trials.

At the 2019 American Academy of Neurology Annual Meeting in Philadelphia, Pennsylvania, Jeffrey Cummings, MD, ScD, director emeritus of the Cleveland Clinic Lou Ruvo Center for Brain Health and vice chair for department of brain health at the University of Nevada Las Vegas, spoke with NeurologyLive in an interview to discuss several hot topics in Alzheimer disease.

Cleveland Clinic's fourth annual analysis of Alzheimer's disease drug development found that the pipeline has grown in the number and variety of agents being tested over the past year, while highlighting several advances in the field including new clinical trial designs, more detailed criteria for making a research diagnosis, and an increased use of biological tests reflecting of the disease.

A nationwide effort to better identify signs of dementia and assist those afflicted with it has made its way to the financial services space.